All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Novel Targets Beyond the JAK-STAT Pathway Aim to Push Myelofibrosis Treatment Forward

May 10th 2024

Anthony M. Hunter, MD, discusses the evolution of myelofibrosis treatment beyond JAK inhibitors.

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

May 9th 2024

Prolonged administration of imatinib maintenance therapy for 6 years improved disease-free survival in patients with gastrointestinal stromal tumors.

Fuzuloparib ± Apatinib Significantly Boosts PFS in BRCA+ HER2– Metastatic Breast Cancer

May 9th 2024

Fuzuloparib with or without apatinib provided superior PFS benefit vs chemotherapy in HER2– metastatic breast cancer harboring germline BRCA1/2 mutations.

Mohty Shares Key Takeaways From the 50th Annual EBMT Meeting, Highlighting Advances in GVHD

May 9th 2024

Mohamad Mohty, MD, PhD, highlights key takeaways from the 50th Annual EBMT Meeting, focusing on ongoing efforts within the GVHD treatment arena.

New Evidence Explains Why Some Targeted Therapies Support Better Response to Cancer Immunotherapy

May 9th 2024

A Roswell Park-led team uncovers beneficial effects of combining VEGFR-targeting TKIs with checkpoint inhibitors in new research.

Adjuvant Pembrolizumab/Chemo Misses Primary End Point of DFS in High-Risk Endometrial Cancer

May 9th 2024

Adjuvant treatment with pembrolizumab plus chemotherapy did not improve DFS vs placebo plus chemotherapy in high-risk endometrial cancer.

CX-904 Generates a Favorable Safety Profile in Phase 1 Trial of EGFR-Expressing Solid Tumors

May 9th 2024

The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.

FDA Grants Breakthrough Device Designation to At-Home Cervical Cancer Screening Test

May 9th 2024

The FDA has granted a breakthrough device designation to Teal Wand, an at-home screening test for cervical cancer.

Improved Survival in Randomized Trials: A Meaningful Outcome but Increasingly Difficult to Demonstrate

May 9th 2024

Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.

Commitments to AML Research Uncover Numerous Targets in Relapsed/Refractory Disease

May 9th 2024

Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.

IBI343 Receives Breakthrough Therapy Designation in China for Claudin 18.2+ Advanced Gastric/GEJ Cancer

May 8th 2024

China's NMPA has granted breakthrough therapy designation to IBI343 for use in select patients with claudin 18.2–positive gastric or GEJ adenocarcinoma.

Pooled Analysis Shows Cytoreduction to Be Safe, Tolerable in Younger Patients With PV

May 8th 2024

Cytoreductive therapy with rIFNα or hydroxyurea is safe and well tolerated in patients with polycythemia vera under the age of 60 years.

FDA Grants Orphan Drug Designation to 9MW2821 for Esophageal Cancer

May 8th 2024

The FDA has granted orphan drug designation to 9MW2821 as a potential treatment for patients with esophageal cancer.

Naumann Dives into Case-by-Case Decision-Making in Ovarian and Endometrial Cancer

May 8th 2024

R. Wendel Naumann, MD, highlights endometrial cancer case studies and how they represent changes in this treatment paradigm.

Action is Key to Continue to Break Down Barriers for Equitable Cancer Care

May 8th 2024

Experts from the University of Wisconsin Health discuss ongoing barriers to equitable cancer care and ways to drive change.

TSP May Predict Chemoresistance and Survival Outcomes in Ovarian Cancer

May 8th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic use of tumor stroma proportion for outcomes and chemoresistance in ovarian cancer.

Health Canada Approves Goserelin Acetate for High-Risk, ER+ Early and Advanced Breast Cancer

May 8th 2024

Health Canada has approved an sNDA for goserelin acetate 10.8 mg every 12 weeks for ER-positive early breast cancer with a high risk of recurrence or advanced breast cancer.

Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses

May 8th 2024

Fox Chase Researchers Examine Alternative Methods of Specialized Imaging Scans for Kidney Masses

Awareness and Early Detection Remain Key Issues in Ovarian Cancer

May 8th 2024

Vaidehi Mujumdar, MD, discusses updates in ovarian cancer for 2024 World Ovarian Cancer Day.

Naumann Spotlights Expanding Arsenals and Evolving Decision-Making in Platinum-Resistant Ovarian Cancer

May 7th 2024

R. Wendel Naumann, MD, discusses 2 case studies in platinum-resistant ovarian cancer and the optimal treatment approaches for each patient.